| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9950069 | UROGEN PHARMA | Material and method for treating internal cavities |
Jan, 2031
(6 years from now) | |
| US9040074 | UROGEN PHARMA | Material and method for treating internal cavities |
Jan, 2031
(6 years from now) | |
Jelmyto is owned by Urogen Pharma.
Jelmyto contains Mitomycin.
Jelmyto has a total of 2 drug patents out of which 0 drug patents have expired.
Jelmyto was authorised for market use on 15 April, 2020.
Jelmyto is available in powder;pyelocalyceal dosage forms.
The generics of Jelmyto are possible to be released after 20 January, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-289) | Apr 15, 2027 |
| New Product(NP) | Apr 15, 2023 |
Drugs and Companies using
MITOMYCIN ingredient
Market Authorisation Date:
15 April, 2020Treatment:
NADosage:
POWDER;PYELOCALYCEAL
More Information on Dosage
JELMYTO family patents
